Cisapride may improve feeding tolerance of preterm infants: A randomized placebo-controlled trial

Biology of the Neonate

Volumn 88, Issue 4, 2005, Pages 270-275

  Kohl, Martina ^a   Wuerdemann, Iris ^a   Clemen, Jessica ^a   Iven, Heiko ^a   Katalinic, Alexander ^a   Moeller, Jens C ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Cisapride; Enteral feeding; Preterm infant

Indexed keywords

CISAPRIDE; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; ELECTROCARDIOGRAM; FEEDING; FEMALE; HEART DISEASE; HUMAN; INFANT; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PREMATURITY; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECORDING;

BIRTH WEIGHT; CISAPRIDE; DIGESTIVE SYSTEM DISEASES; ELECTROCARDIOGRAPHY; ENTERAL NUTRITION; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL TRANSIT; HUMANS; INFANT FORMULA; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; MALE; MILK, HUMAN; PLACEBOS; TIME FACTORS; TREATMENT OUTCOME;

EID: 27844495738     PISSN: 00063126     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087623     Document Type: Article

References (23)

1. Berseth CL: Feeding and maturation of gut motility; in Ziegler EE, Moro GE (eds): Nestlé Nutrition Workshop Series, Paediatric Programme. Nutrition of the Very Low Birth Weight Infant. Vevey/Philadelphia, Nestec/ Lippincott Williams & Wilkins, 1999, vol 43, pp 211-220.
2. Shulman RJ, Schanler RJ, Lau C, Heitkemper M, Ou CN, O'Brian Smith E: Early feeding, feeding tolerance, and lactase activity in pre-term infants. J Pediatr 1998;133:645-649.
3. Kennedy KA, Tyson JE, Chamnanvanikij S: Early versus delayed initiation of progressive enteral feedings for parenterally fed low birth weight or preterm infants. Cochrane Database Syst Rev 2000;12:CD001970.
4. Wiseman DF: Cisapride: an updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994;47:116-152.
5. Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM: Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001;96:1698-1703.
6. Costalos C, Gounaris A, Varhalama E, Kokori F, Alexiou N, Katsarakis I: Effect of low-dose cisapride on gastric emptying and QTc interval in preterm infants. Acta Paediatr 2000;89:1446-1448.
7. Enriquez A, Bolisetty S, Patole S, Garvey PA, Campbell PJ: Randomised controlled trial of cisapride in feed intolerance in preterm infants. Arch Dis Child Fetal Neonatal Ed 1998;79:F110-F113.
8. McClure RJ, Kristensen JH, Grauaug A: Randomised controlled trial of cisapride in pre-term infants. Arch Dis Child Fetal Neonatal Ed 1999;80:F174-F177.
9. Garson A Jr: How to measure the QT interval - what is normal? Am J Cardiol 1993;72:14B-16B.
10. Villain E, Levy M, Kachaner J, Garson A Jr: Prolonged QT interval in neonates: benign, transient, or prolonged risk of sudden death. Am Heart J 1992;124:194-197.
11. Preechagoon Y, Charles B, Piotrovskij V, Donovan T, Van Peer A: Population pharmacokinetics of enterally administered cisapride in young infants with gastro-oesophageal reflux disease. Br J Clin Pharmacol 1999;48:688-693.
12. Williams AF: Early enteral feeding of the pre-term infant. Arch Dis Child Fetal Neonatal Ed 2000;83:F219-F220.
13. Ariagno RL, Kikkert MA, Mirmiran M, Conrad C, Baldwin RB: Cisapride decreases gastroesophageal reflux in preterm infants. Pediatrics 2001;107:E58.
14. Griffin JP: Prepulsid withdrawn from UK and US markets. Adverse Drug React Toxicol Rev 2000;19:177.
15. Bernardini S, Semama DS, Huet F, Sgro C, Gouyon JB: Effects of cisapride on QTc interval in neonates. Arch Dis Child Fetal Neonatal Ed 1997;77:F241-F243.
16. Semama DS, Bernardini S, Louf S, Laurent-Atthalin B, Gouyon JB: Effects of cisapride on QTc interval in term neonates. Arch Dis Child Fetal Neonatal Ed 2001;84:F44-F46.
17. van Peer A, Verlinden M, Woestenborghs R, Meuldermanns W, Heykants J, Reyntjens A. Clinical pharmacokinetics of cisapride; in Johnson AG, Lux G (eds): Progress in the Treatment of Gastrointestinal Motility Disorders: The Role of Cisapride. Amsterdam, Excerpta Medica, 1988, pp 23-29.
18. Treluyer JM, Rey E, Sonnier M, Pons G, Cresteil T: Evidence of impaired cisapride metabolism in neonates. Br J Clin Pharmacol 2001;52: 419-425.
19. Janssens G, Melis K, Vaerenberg M: Long-term use of cisapride (prepulsid) in premature neonates of less than 34 weeks gestational age. J Pediatr Gastroenterol Nutr 1990;11:420-422.
20. Ward RM, Lemons JA, Molteni RA: Cisapride: a survey of the frequency of use and adverse events in premature newborns. Pediatrics 1999;103:469-472.
21. Maillard C, Boutroy MJ, Fresson J, Barbe F, Hascoet JM: QT interval lengthening in pre-mature infants treated with doxapram. Clin Pharmacol Ther 2001;70:540-545.
22. Dubin A, Kikkert M, Mirmiran M, Ariagno R: Cisapride associated with QTc prolongation in very low birth weight preterm infants. Pediatrics 2001;107:1313-1316.
23. Shulman RJ, Boyle JT, Colletti RB, Friedman RA, Heyman MB, Kearns G, Kirschner BS, Levy J, Mitchell AA, Van Hare G: The use of cisapride in children. The North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 1999;28:529-533.